News headlines about Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been trending somewhat positive this week, according to Alpha One. The research firm, a unit of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics PLC – earned a daily sentiment score of 0.14 on Alpha One’s scale. Alpha One also gave media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Alpha One Sentiment Analysis’s scoring:
- Adaptimmune Therapeutics : Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors (4-traders.com)
- BRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy (reuters.com)
- ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events (4-traders.com)
- Dividend Spotlight on Adaptimmune Therapeutics plc (NasdaqGS … – Geneva Journal (genevajournal.com)
- Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors (finance.yahoo.com)
Several research analysts have commented on ADAP shares. Wells Fargo & Co assumed coverage on shares of Adaptimmune Therapeutics PLC – in a report on Friday, March 17th. They issued a “market perform” rating for the company. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a “sell” rating to a “hold” rating in a research report on Friday, March 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $11.83.
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) opened at 5.39 on Friday. The company’s market cap is $503.94 million. Adaptimmune Therapeutics PLC – has a 12 month low of $3.76 and a 12 month high of $11.59. The company’s 50-day moving average is $5.46 and its 200 day moving average is $4.64.
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.06. Adaptimmune Therapeutics PLC – had a negative net margin of 667.22% and a negative return on equity of 31.56%. The company had revenue of $2.86 million for the quarter, compared to the consensus estimate of $5.07 million. Equities analysts forecast that Adaptimmune Therapeutics PLC – will post ($1.04) earnings per share for the current fiscal year.
In other news, major shareholder Enterprise Associates 14 New acquired 12,870,000 shares of the business’s stock in a transaction dated Monday, March 27th. The stock was purchased at an average cost of $0.70 per share, for a total transaction of $9,009,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc acquired 1,190,476 shares of the business’s stock in a transaction dated Monday, March 27th. The stock was purchased at an average price of $4.20 per share, with a total value of $4,999,999.20. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics PLC – (ADAP) Earns Daily Media Impact Rating of 0.14” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://sportsperspectives.com/2017/05/20/adaptimmune-therapeutics-plc-adap-getting-somewhat-favorable-media-coverage-analysis-finds-updated-updated.html.
About Adaptimmune Therapeutics PLC –
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC - and related companies with MarketBeat.com's FREE daily email newsletter.